GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shanghai Fosun Pharmaceutical (Group) Co Ltd (SHSE:600196) » Definitions » Beneish M-Score

Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) Beneish M-Score : -2.43 (As of Dec. 12, 2024)


View and export this data going back to 1998. Start your Free Trial

What is Shanghai Fosun Pharmaceutical (Group) Co Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.43 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Shanghai Fosun Pharmaceutical (Group) Co's Beneish M-Score or its related term are showing as below:

SHSE:600196' s Beneish M-Score Range Over the Past 10 Years
Min: -2.55   Med: -2.33   Max: -2.12
Current: -2.43

During the past 13 years, the highest Beneish M-Score of Shanghai Fosun Pharmaceutical (Group) Co was -2.12. The lowest was -2.55. And the median was -2.33.


Shanghai Fosun Pharmaceutical (Group) Co Beneish M-Score Historical Data

The historical data trend for Shanghai Fosun Pharmaceutical (Group) Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Fosun Pharmaceutical (Group) Co Beneish M-Score Chart

Shanghai Fosun Pharmaceutical (Group) Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.34 -2.30 -2.14 -2.31 -2.52

Shanghai Fosun Pharmaceutical (Group) Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.47 -2.52 -2.55 -2.52 -2.43

Competitive Comparison of Shanghai Fosun Pharmaceutical (Group) Co's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Fosun Pharmaceutical (Group) Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Fosun Pharmaceutical (Group) Co's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shanghai Fosun Pharmaceutical (Group) Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Shanghai Fosun Pharmaceutical (Group) Co's Beneish M-Score falls into.



Shanghai Fosun Pharmaceutical (Group) Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Shanghai Fosun Pharmaceutical (Group) Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.1135+0.528 * 1.0198+0.404 * 1.0139+0.892 * 0.9671+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.829+4.679 * -0.015836-0.327 * 0.9824
=-2.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Sep23) TTM:
Total Receivables was ¥9,820 Mil.
Revenue was 10449.076 + 10305.557 + 10157.255 + 10699.421 = ¥41,611 Mil.
Gross Profit was 5022.862 + 4919.878 + 5079.549 + 4883.633 = ¥19,906 Mil.
Total Current Assets was ¥34,527 Mil.
Total Assets was ¥115,265 Mil.
Property, Plant and Equipment(Net PPE) was ¥21,861 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥6,714 Mil.
Total Current Liabilities was ¥37,518 Mil.
Long-Term Debt & Capital Lease Obligation was ¥11,087 Mil.
Net Income was 785.844 + 615.065 + 609.734 + 103.2 = ¥2,114 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = ¥0 Mil.
Cash Flow from Operations was 1079.633 + 989.692 + 917.312 + 952.577 = ¥3,939 Mil.
Total Receivables was ¥9,119 Mil.
Revenue was 9304.926 + 10524.472 + 10870.721 + 12328.777 = ¥43,029 Mil.
Gross Profit was 4223.926 + 5120.745 + 5575.927 + 6071.575 = ¥20,992 Mil.
Total Current Assets was ¥34,914 Mil.
Total Assets was ¥110,767 Mil.
Property, Plant and Equipment(Net PPE) was ¥20,052 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥8,375 Mil.
Total Current Liabilities was ¥34,506 Mil.
Long-Term Debt & Capital Lease Obligation was ¥13,041 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(9820.187 / 41611.309) / (9119.422 / 43028.896)
=0.235998 / 0.211937
=1.1135

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(20992.173 / 43028.896) / (19905.922 / 41611.309)
=0.487862 / 0.478378
=1.0198

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (34527.299 + 21861.334) / 115264.762) / (1 - (34914.165 + 20052.285) / 110767.244)
=0.51079 / 0.503766
=1.0139

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=41611.309 / 43028.896
=0.9671

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 20052.285)) / (0 / (0 + 21861.334))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(6714.037 / 41611.309) / (8374.905 / 43028.896)
=0.161351 / 0.194634
=0.829

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((11087.42 + 37517.582) / 115264.762) / ((13040.706 + 34506.298) / 110767.244)
=0.421681 / 0.429251
=0.9824

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(2113.843 - 0 - 3939.214) / 115264.762
=-0.015836

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Shanghai Fosun Pharmaceutical (Group) Co has a M-score of -2.43 suggests that the company is unlikely to be a manipulator.


Shanghai Fosun Pharmaceutical (Group) Co Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Shanghai Fosun Pharmaceutical (Group) Co's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Fosun Pharmaceutical (Group) Co Business Description

Address
No. 1289 Yishan Road, Building A, Fosun Technology Park, Shanghai, CHN, 200233
Shanghai Fosun Pharmaceutical (Group) Co Ltd is engaged in the development, manufacture, and sale of pharmaceutical products and medical equipment, the import and export of medical equipment, and the provision of related and other consulting services and investment management. Its business segments are Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. It generates the majority of its revenue from the Pharmaceutical manufacturing segment. The company considers merger and acquisition investment as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities. Its geographic areas are the Chinese mainland, Regions outside the Chinese mainland, and other countries.
Executives
Wu Yi Fang Director
Wen De Yong Directors, senior managers
Guan Xiao Hui Director
Wang Ke Xin Director
Bao Qin Gui senior management
Mei Jing Ping senior management
Li Sheng Li senior management
Feng Rong Li senior management
Wang Dong Hua senior management
Dong Xiao Xian senior management
Su Li senior management
Zhu Yue senior management
Chen Yu Qing senior management
Hu Hang senior management
Liu Yi senior management

Shanghai Fosun Pharmaceutical (Group) Co Headlines

No Headlines